Loading stock data…
GRCE
$2.34+0.10 (+4.46%)
Market ClosedLast close May 1
Grace Therapeutics, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Grace Therapeutics, Inc. in the Healthcare sector is trading at $2.34. The stock is currently near its 52-week low of $1.79, remaining 32.0% below its 200-day moving average. Technical signals show oversold RSI of 30 and bearish MACD signal, explaining why GRCE maintains its current current market pressure. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Oversold momentum (RSI 30) — potential for technical mean-reversion
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$2.34
Potential Upside
5%
Whystock Fair Value$2.46
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$66.69M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.69
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-9.21%
Volume
Today's trading volume
785,502
Recent News
Sector Update: Health Care Stocks Edge Lower Late Afternoon
Health care stocks were softer late Thursday afternoon, with the NYSE Health Care Index and the Stat
We're Not Very Worried About Grace Therapeutics' (NASDAQ:GRCE) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, Grace...
This Grace Therapeutics Insider Increased Their Holding By 12% Last Year
Insiders were net buyers of Grace Therapeutics, Inc.'s ( NASDAQ:GRCE ) stock during the past year. That is, insiders...
We Think Grace Therapeutics (NASDAQ:GRCE) Needs To Drive Business Growth Carefully
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Grace Therapeutics, Inc. (NASDAQ:GRCE) Is Expected To Breakeven In The Near Future
Grace Therapeutics, Inc. ( NASDAQ:GRCE ) is possibly approaching a major achievement in its business, so we would like...